Hyderabad, India, June 07, 2012  

Dr. Reddy’s announces the Launch of Ropinirole Hydrochloride XR (Extended-Release) Tablets

Hyderabad, India, June 07, 2012

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Ropinirole Hydrochloride XR (Extended-Release) tablets (2 mg, 4 mg, 6 mg, 8mg, and 12 mg), a bioequivalent generic version of REQUIP XL® tablets in the US market on June 06, 2012 following the approval by the United States Food & Drug Administration (USFDA) of Dr. Reddy’s ANDA for Ropinirole Hydrochloride XR (extended-Release) tablets.

The REQUIP XL® brand had U.S. sales of approximately $58 million for the most recent twelve months ending March 2012 according to IMS Health.

Dr. Reddy’s Ropinirole Hydrochloride XR (Extended-Release) tablets in 2 mg, 4 mg and 6 mg are available in 30 and 90 count bottle sizes, 8 mg and 12 mg are available in 30 count bottle sizes.

This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.

About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to:

REQUIP XL® tablets are a registered trademark of SmithKline Beecham Limited.

IMS National Sales Perspectives: Retail and Non-Retail MAT March 2012

For more information please contact:

Investors and Financial Analysts:
Kedar Upadhye at / +91-40-66834297
Raghavender R at /+91-40-49002135
Saunak Savla at / +91-40-49002135
Milan Kalawadia (North America) at or at 908-203-4931

S Rajan at / +91-40-49002445